Alain Makinson 06 63 07 52 60 / 04 67 33 95 10 firstname.lastname@example.org
Thanks to antiretroviral therapies, it is possible to grow old with HIV under control. However, this chronic infection may not leave cognitive function unscathed. That is why Alain Makinson (Translational Research on HIV and Infectious Diseases unit, Montpellier University Hospital, Université de Montpellier, Inserm, IRD) and his team were interested in exploring the development of neurocognitive impairment (NCI), such as diminished attention, memory and motor capacity, in patients living with HIV in the ANRS EP58 HAND 55-70 study. In their latest research, published in Clinical Infectious diseases, the scientists describe the results of their observations of 200 people living with HIV enrolled in six French centers. The data collected from these patients were then compared, using the same neurocognitive evaluation methods, with those of a control population of 1,000 people of the same age, sex and education taken from Constances – a cohort recruited from the general population, with over 200,000 volunteers. The researchers reveal that among those living with HIV between the ages of 55 and 70, the risk of developing mild (and in some cases, symptomless) neurocognitive impairment increases by 50%.
Thanks to antiretroviral therapies, people living with the human immunodeficiency virus (PLHIV) can bring it under control. However, while HIV is no longer their major cause of death – having decreased substantially since the advent of these therapies – other risks must be considered. Several recent studies have highlighted the increased prevalence of neurocognitive impairment (NCI) in PLHIV compared with uninfected individuals – an increase that is all the more pronounced in those whose virus is not controlled. However, this NCI could also be caused by cardiovascular factors or the onset of depression, which is more common in this population.
In order to try to determine the nature of the link between living with HIV and developing NCI (such as diminished attention, memory and motor capacity), Alain Makinson and his coworkers studied the data of 200 PLHIV, between 55 and 70 years of age, whose HIV was under control and who were enrolled between January 2016 and October 2017 in the ANRS EP58 HAND (HIV-Associated Neurocognitive Disorder) study. Each patient was compared with five HIV-uninfected individuals of the same age, sex and education, from Constances – a cohort recruited from the general population. The same methods were used for both populations when performing the cognitive tests and collecting the study data. All in all, 1,200 people took part in this study.
Although the impairments observed in the study were either mild or without apparent symptoms (i.e. with zero to low impact on daily activities despite abnormal test results), those living with HIV were more affected by NCI: 35% versus 24% for the control group.
Despite these highly robust results, a causal link between living with HIV and developing NCI cannot be established – for which there are several possible hypotheses. One is that HIV infection and its treatments cause recurrent brain inflammation. Another is that the complications associated with the immune deficiency can affect cognition before antiretroviral treatment is initiated, but without the subsequent deterioration occurring more rapidly in comparison with the general population. Finally, seropositivity could be associated with other risk factors (particularly drug use), which are difficult to measure fully in the two populations of this study.
The authors wish to continue to follow the same population over a longer period in order to better define the causes of NCI in this aging population and test the hypothesis of accelerated cognitive aging in PLHIV – particularly given that very few studies with a control group are available. Testing the brain inflammation hypothesis by collecting certain specific blood biomarkers represents another avenue for the team to explore in its quest to elucidate the mechanisms behind NCI.
A research team from Inserm, Lille University, Lille University Hospital, CNRS, and the Institut Pasteur of Lille, as part of the Lille Immunity and Infection Center, is developing a new vaccine against whooping cough. En utilisant la bactérie entière mais génétiquement modifiée ...
Pour la première fois depuis l’apparition du virus Ebola, des survivants ont été suivis pendant 48 mois au sein d’une cohorte, appelée « PostEboGui ». Même si les symptômes diminuent significativement dans le temps, de nombreux patients présentent encore des séquelles quatre ans après ...
Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55–70 Study. Clinical Infectious Diseases, 25 July 2019 Alain Makinson,1,2 Jonathan Dubois,3 Sabrina Eymard-Duvernay,2 Pascale Leclercq,4 Olivia Zaegel-Faucher,5 Louis Bernard,6 Matteo Vassallo,7 Claudine Barbuat,8 Christian Gény,9 Eric Thouvenot,10 Dominique Costagliola,11 Anna Ozguler,12 Marie Zins,12 Mélanie Simony,13 Jacques Reynes,1,2 and Claudine Berr3 1 Infectious and Tropical Diseases Department, University Hospital Montpellier 2 Institut de Recherche et Développement, Institut National de la Santé et de la Recherche Médicale (French Institute of Health and Medical Research) (INSERM), University of Montpellier TransVIHMI Unit 3 INSERM, University of Montpellier, Neuropsychiatry: Epidemiological and Clinical Research; 4 Infectious Disease Unit, University Hospital of Grenobles Alpes, and Fédération d’Infectiologie Multidisciplinaire de l’Arc Alpin, Université Grenoble Alpes; 5 Clinical Immuno-Hematology Department, Aix- Marseille University, Sainte-Marguerite University Hospital, Marseille 6 Infectious Diseases Unit, University Hospital Tours 7 Department of Internal Medicine, Cannes General Hospital 8 Infectious Diseases Department, University Hospital, Nîmes 9 Neurology Department, Montpellier University Hospital Center, Gui de Chauliac Hospital 10 Neurology Department, University Hospital, Nîmes 11 Sorbonne University, INSERM, Institut Pierre Louis d’Épidémiologie et de Santé Publique (IPLESP), Paris 12 INSERM, Paris Descartes University Population-based Epidemiological Cohorts Unit, Villejuif 13 ANRS (France Recherche Nord & Sud Sida-HIV Hépatites), Unit for Basic and Clinical Research on Viral Hepatitis and HIV, Paris, France